scholarly journals Use of Aspirin, Other Nonsteroidal Anti-Inflammatory Drugs, and Acetaminophen and Postmenopausal Breast Cancer Incidence

2012 ◽  
Vol 30 (28) ◽  
pp. 3468-3477 ◽  
Author(s):  
Xuehong Zhang ◽  
Stephanie A. Smith-Warner ◽  
Laura C. Collins ◽  
Bernard Rosner ◽  
Walter C. Willett ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Cancer Incidence ◽  
Molecular Subtype ◽  
Breast Cancer Incidence ◽  
Postmenopausal Breast Cancer ◽  
Luminal A ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Anti Inflammatory

Purpose The associations between use of aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen and breast cancer incidence in postmenopausal women are uncertain. We examined these associations with breast cancer, both overall and by molecular subtype. Patients and Methods We observed 84,602 postmenopausal women, free of cancer in 1980, until June 2008 and prospectively collected data on analgesic use, reproductive history, and other lifestyle factors using biennial questionnaires. Proportional hazards models were used to estimate multivariable relative risks (RRs) and 95% CIs. Results We documented 4,734 cases of incident invasive breast cancer. Compared with nonuse of aspirin, multivariable RRs of regular aspirin use (≥ two tablets per week) for more than 20 years were 0.91 for overall breast cancer (95% CI, 0.81 to 1.01; Ptrend = 0.16), 0.90 for estrogen receptor (ER) –positive progesterone receptor (PR) –positive breast cancer (95% CI, 0.77 to 1.06; Ptrend = 0.17), and 0.91 for ER-negative PR-negative breast cancer (95% CI, 0.68 to 1.22; Ptrend = 0.97). Results did not vary appreciably by past or current use, days per week of use, or dosage of use. Use of other NSAIDs and acetaminophen was largely not significantly associated with breast cancer risk. Additionally, use of higher doses of each analgesic (≥ six tablets per week) for more than 10 years was generally not significantly associated with risk of breast cancer, either overall or by subtype. Furthermore, largely no substantial associations were noted for breast cancer molecular subtypes, including luminal A, luminal B, triple negative, basal-like, human epidermal growth factor receptor 2 positive, cyclooxygenase-2 (COX-2) negative, and COX-2 positive. Conclusion Our study suggests that use of aspirin, other NSAIDs, and acetaminophen is not importantly associated with risk of postmenopausal breast cancer, either overall or by specific subtype.

Influence of the dramatic fall of hormone replacement therapy (HRT) prescription on postmenopausal breast cancer incidence: The Austrian data

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1529-1529
Author(s):  
G. Pfeiler ◽  
C. Glatz ◽  
R. Königsberg ◽  
C. Vutuc ◽  
E. Kubista ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Cancer Incidence ◽  
Hormone Receptor ◽  
Breast Cancer Incidence ◽  
Postmenopausal Breast Cancer ◽  
Receptor Expression ◽  
Incidence Data ◽  
Cancer Incidence Data ◽  
Dramatic Fall

1529 Background: The Women's Health Initiative trial showed a significant increase in breast cancer risk among women using HRT. This publication led to a dramatic fall in HRT prescription worldwide. Several studies argued that the ensuing decline in breast cancer incidence among postmenopausal women was due to the reduced HRT prescriptions. We have investigated whether the strong decline in HRT prescription in Austrian women from 2002 onward was associated with a decrease in postmenopausal breast cancer incidence in Austria. Methods: Breast cancer incidence data were obtained from the National Austrian Cancer Registry. HRT prescription data were calculated using Pharmaceutical Benefits Scheme data. Hormone receptor expression data were taken from the pathology report of all patients with breast cancer, who were operated on at the Division of Special Gynecology, as well as the Department of Surgery, Medical University of Vienna (MUW), from 1998 to 2000, and 2005 to 2007, respectively. Chi-Square test was used to identify significant differences. Results: HRT prescription slightly increased from 1998 to 2000, but dramatically decreased by 70% after 2003, reaching a significantly lower level. When comparing breast cancer incidence data from 1999 and 2004, a nonsignificant trend toward a decreased incidence in 50- to 54-year-old women could be observed. Comparing predicted breast cancer incidence for 2004 with the actual incidence for 2004 in this group, a significant decrease could be demonstrated. Ten percent to 12% of all new breast cancers in Austria are treated at the MUW every year. Regarding histopathologic breast cancer parameters of patients treated at the MUW from 1998 to 2000 and 2005 to 2007, respectively, a nonsignificant decline of hormone receptor positive tumors in 50- to 54-year-old patients with breast cancer could be observed. Conclusions: The decline of HRT use in Austria is associated with a reduction in breast cancer incidence in postmenopausal women. Our data underline the association between HRT and breast cancer. No significant financial relationships to disclose.

scholarly journals Weight loss, diet composition and breast cancer incidence and outcome in postmenopausal women

Oncotarget ◽  
2019 ◽  
Vol 10 (33) ◽  
pp. 3088-3092 ◽  
Author(s):  
Kathy Pan ◽  
Juhua Luo ◽  
Aaron K. Aragaki ◽  
Rowan T. Chlebowski
Keyword(s):  
Breast Cancer ◽  
Weight Loss ◽  
Postmenopausal Women ◽  
Cancer Incidence ◽  
Diet Composition ◽  
Breast Cancer Incidence ◽  
Weight Loss Diet

Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women’s Health Initiative

Cancer ◽  
2020 ◽  
Vol 126 (16) ◽  
pp. 3638-3647
Author(s):  
Kathy Pan ◽  
Rowan T. Chlebowski ◽  
Joanne E. Mortimer ◽  
Marc J. Gunther ◽  
Thomas Rohan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Insulin Resistance ◽  
Women's Health ◽  
Postmenopausal Women ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Women's Health Initiative ◽  
Health Initiative ◽  
Incidence And Mortality ◽  
The Women’S Health Initiative

scholarly journals Dietary Energy Density and Postmenopausal Breast Cancer Incidence in the Cancer Prevention Study II Nutrition Cohort

2016 ◽  
Vol 146 (10) ◽  
pp. 2045-2050 ◽  
Author(s):  
Terryl J Hartman ◽  
Susan M Gapstur ◽  
Mia M Gaudet ◽  
Roma Shah ◽  
W Dana Flanders ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Energy Density ◽  
Cancer Prevention ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Postmenopausal Breast Cancer ◽  
Dietary Energy ◽  
Prevention Study ◽  
Dietary Energy Density

scholarly journals Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Manon Cairat ◽  
Marie Al Rahmoun ◽  
Marc J. Gunter ◽  
Gianluca Severi ◽  
Laure Dossus ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Prospective Cohort ◽  
Cox Regression ◽  
Insurance Plan ◽  
Anticancer Properties ◽  
Hazard Ratios ◽  
Reimbursement Database ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract Background Although anti-inflammatory agents could theoretically have anticancer properties, results from cohort studies on nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer (BC) risk are inconsistent. Methods We investigated the association between NSAID use and BC incidence in the French E3N prospective cohort, which includes 98,995 women born between 1925 and 1950 and insured by a health insurance plan that covers mostly teachers. Self-reported information on lifestyle and medical history has been collected biennially by questionnaires and matched with data from a drug reimbursement database covering the period 2004–2014. Women who self-reported current NSAID use in the 2000 or 2002 questionnaires or with at least two reimbursements in any previous 3-month period were defined as exposed to NSAIDs. Multivariable Cox regression models were used to estimate hazard ratios (HRs) for the association of NSAID use with BC risk. Results In the current analysis, 62,512 postmenopausal women were followed between 2004 and 2014 (9 years on average, starting at a mean age of 63 years; 2864 incident BC). In multivariable models, there was no statistically significant association between NSAID use and BC risk [HR = 1.00 (0.92–1.08), compared with non-exposed women]. The NSAID-BC associations did not differ by NSAID types, BC subtypes, risk factors, and comorbidities, nor by duration and dose of use. However, a statistically significant interaction was observed by proton pump inhibitor (PPI) drug use (Pinteraction = 0.01) whereby a decreased risk of BC with NSAID use was only observed among women who also used PPI before. Conclusion Only women who used NSAIDs after having used PPI had a lower risk of BC. This result is novel and requires replication in other studies.

scholarly journals The Association Between Phytosterol Intake and Breast Cancer Incidence in the Adventist Health Study-2 Cohort

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 352-352
Author(s):  
Rawiwan Sirirat ◽  
Yessenia Tantamango-Bartley ◽  
Celine Heskey ◽  
Ella Haddad ◽  
Gary Fraser ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Premenopausal Women ◽  
Epidemiological Studies ◽  
Health Study ◽  
Breast Cancer Cell Lines ◽  
Inverse Association ◽  
Adventist Health Study

Abstract Objectives Breast cancer is the most diagnosed form of cancer among American women. Worldwide, it is second only to lung cancer. Phytosterols are phytochemicals found in plant foods that have potential benefits for breast cancer. Research on phytosterols and cancer associations to date has been limited to breast cancer cell lines and animal studies, and the results have been promising. Our objective is to examine the association between breast cancer incidence and phytosterol intake in the Adventist Health Study-2, a large cohort in North America. Methods The present study estimated the association between phytosterol intake and breast cancer incidence in 52,734 females who were part of the Adventist Health Study 2 (AHS-2) cohort. Breast cancer cases (n = 1050) were ascertained with tumor registries from 2008 to 2014. Phytosterols content in foods was quantified by using USDA 17 and other published sources. These values were used to estimate phytosterol intake from food intake assessed by a self-administered food frequency questionnaires (FFQ). Results Hazard ratios were below the null, but statistically non-significant for β-sitosterol [HR = 0.77, 95%CI (0.44–1.36)], campesterol [HR = 0.84, 95%CI (0.46–1.55)], stigmasterol [HR = 0.76 (0.46–1.26)], and total phytosterol [HR = 0.77, 95%CI (0.43–1.40)]. In premenopausal women, HRs ranged between 0.95–1.72; in postmenopausal women, HRs were below the null, ranging between 0.67–0.83. In both premenopausal and postmenopausal women, HRs were statistically non-significant. Conclusions The inverse association between phytosterol consumption and breast cancer incidence appears uncertain. The uncertainty possibly could be due to lack of power or measurement error. Additional epidemiological studies with a larger number of breast cancer cases, improved phytosterol intake estimates, or both are needed. Funding Sources Unilever Research &Development, Vlaardingen, The Netherlands.

scholarly journals Diabetes, Metformin, and Breast Cancer in Postmenopausal Women

2012 ◽  
Vol 30 (23) ◽  
pp. 2844-2852 ◽  
Author(s):  
Rowan T. Chlebowski ◽  
Anne McTiernan ◽  
Jean Wactawski-Wende ◽  
JoAnn E. Manson ◽  
Aaron K. Aragaki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Cancer Incidence ◽  
Proportional Hazards ◽  
Breast Cancer Incidence ◽  
Cox Proportional Hazards ◽  
Diabetes Incidence ◽  
Breast Cancers ◽  
Cancer Risk Factors ◽  
Cancer Management

Purpose Emerging evidence suggests that metformin may reduce breast cancer incidence, but reports are mixed and few provide information on tumor characteristics. Therefore, we assessed associations among diabetes, metformin use, and breast cancer in postmenopausal women participating in Women's Health Initiative clinical trials. Patients and Methods In all, 68,019 postmenopausal women, including 3,401 with diabetes at study entry, were observed over a mean of 11.8 years with 3,273 invasive breast cancers diagnosed. Diabetes incidence status was collected throughout follow-up, with medication information collected at baseline and years 1, 3, 6, and 9. Breast cancers were confirmed by review of central medical records and pathology reports. Cox proportional hazards regression, adjusted for breast cancer risk factors, compared breast cancer incidence in women with diabetes who were metformin users or nonusers with breast cancer incidence in women without diabetes. Results Compared with that in women without diabetes, breast cancer incidence in women with diabetes differed by diabetes medication type (P = .04). Women with diabetes receiving medications other than metformin had a slightly higher incidence of breast cancer (hazard ratio [HR], 1.16; 95% CI, 0.93 to 1.45), and women with diabetes who were given metformin had lower breast cancer incidence (HR, 0.75; 95% CI, 0.57 to 0.99). The association was observed for cancers positive for both estrogen receptor and progesterone receptor and those that were negative for human epidermal growth factor receptor 2. Conclusion Metformin use in postmenopausal women with diabetes was associated with lower incidence of invasive breast cancer. These results can inform future studies evaluating metformin use in breast cancer management and prevention.

Sign in / Sign up

Export Citation Format

Share Document